Relmada reports FY 2023 net loss of $98.8M; advancing Phase 3 MDD trials with data expected H2 2024

RELMADA THERAPEUTICS, INC.

Q4 2023 net loss $25.2M ($0.84/share) vs $37.9M ($1.28) in Q4 2022; full-year net loss $98.8M ($3.28/share).
Cash, equivalents and short-term investments at Dec 31, 2023: $96.3M, down from $148.3M a year earlier.
R&D expense fell to $54.8M in FY 2023 from $113.3M in FY 2022, reflecting completion of prior Phase 3 trials.
REL-1017 Phase 3 Reliance II enrollment on track; top-line data expected H2 2024; Relight enrollment targeted by year-end 2024.
REL-P11 psilocybin Phase 1 in obese patients expected H1 2024; Phase 2a proof-of-concept data seen H1 2025.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

RELMADA THERAPEUTICS, INC. reported the fourth quarter and full year ended December 31, 2023 results: net income $98.8 million, EPS $3.28 per basic and diluted share.

Period: the fourth quarter and full year ended December 31, 2023
Net income: $98.8 million
EPS: $3.28 per basic and diluted share
Result: preliminary results

Exact text from the filing

Relmada Therapeutics, Inc. (the “Company”) issued a press release providing a corporate update and reporting its financial results for the fourth quarter and full year ended December 31, 2023. (These results are preliminary and unaudited.)

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

RELMADA THERAPEUTICS, INC. reported the fourth quarter and full year ended December 31, 2023 results: net income $98.8 million, EPS $3.28 per basic and diluted share.

Period: the fourth quarter and full year ended December 31, 2023
Net income: $98.8 million
EPS: $3.28 per basic and diluted share
Result: preliminary results

Exact text from the filing

Net loss for the year ended December 31, 2023 and 2022 was $98.8 million and $157.0 million, respectively. The Company had a net loss of $3.28 and $5.30 per basic and diluted share for the year ended December 31, 2023 and 2022, respectively.

View on SEC.gov

20 earnings releases filed in the last 30 days. Browse all earnings releases →

RELMADA THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001213900-24-024022

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.